Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Acquired by CreativeOne Wealth LLC

CreativeOne Wealth LLC increased its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 38.9% during the 4th quarter, Holdings Channel reports. The fund owned 7,175 shares of the medical equipment provider’s stock after purchasing an additional 2,008 shares during the quarter. CreativeOne Wealth LLC’s holdings in Lantheus were worth $642,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of LNTH. Synovus Financial Corp boosted its position in Lantheus by 13.4% in the 4th quarter. Synovus Financial Corp now owns 25,639 shares of the medical equipment provider’s stock worth $2,294,000 after purchasing an additional 3,038 shares in the last quarter. Granite Investment Partners LLC lifted its stake in shares of Lantheus by 3.2% in the 4th quarter. Granite Investment Partners LLC now owns 51,149 shares of the medical equipment provider’s stock valued at $4,576,000 after purchasing an additional 1,579 shares during the period. Townsquare Capital LLC purchased a new stake in Lantheus during the fourth quarter worth $1,108,000. Capital Fund Management S.A. grew its position in Lantheus by 180.5% during the fourth quarter. Capital Fund Management S.A. now owns 99,573 shares of the medical equipment provider’s stock valued at $8,908,000 after buying an additional 64,078 shares during the period. Finally, Raymond James Financial Inc. purchased a new position in Lantheus in the fourth quarter valued at $36,183,000. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Lantheus

In other Lantheus news, CFO Robert J. Jr. Marshall sold 10,000 shares of the company’s stock in a transaction on Monday, March 17th. The stock was sold at an average price of $100.52, for a total value of $1,005,200.00. Following the completion of the sale, the chief financial officer now directly owns 113,860 shares in the company, valued at $11,445,207.20. This represents a 8.07 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Mary Anne Heino sold 53,107 shares of Lantheus stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total value of $5,010,645.45. Following the transaction, the director now owns 440,399 shares in the company, valued at approximately $41,551,645.65. This represents a 10.76 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 63,109 shares of company stock valued at $6,016,046. Corporate insiders own 1.50% of the company’s stock.

Lantheus Price Performance

Shares of Lantheus stock opened at $101.32 on Friday. The stock has a market capitalization of $6.94 billion, a P/E ratio of 16.86 and a beta of 0.20. The business has a 50 day simple moving average of $95.00 and a two-hundred day simple moving average of $95.55. Lantheus Holdings, Inc. has a 12 month low of $61.47 and a 12 month high of $126.89.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.23). The firm had revenue of $391.11 million during the quarter, compared to analysts’ expectations of $376.61 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. As a group, research analysts anticipate that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Analyst Ratings Changes

LNTH has been the topic of several recent analyst reports. JMP Securities reissued a “market outperform” rating and set a $112.00 target price on shares of Lantheus in a research note on Tuesday, January 14th. B. Riley dropped their price objective on Lantheus from $127.00 to $122.00 and set a “buy” rating on the stock in a report on Friday, March 21st. Finally, Truist Financial boosted their price objective on Lantheus from $120.00 to $127.00 and gave the company a “buy” rating in a research report on Thursday, February 27th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $129.43.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.